InfiniTrak - Covering DSCSA Compliance for The Medical Spa Show
It is not just pharmacies, LTC facilities, clinics, and hospitals anymore — the FDA is cracking down on med spas for DSCSA compliance.
“You’re a booth I need to speak with,” Aaron gushed as he headed into the convention floor. As the only group of people as familiar with the Drug Supply Chain Security act, we were equally enthused for the conversation!
The FDA’s Senior Regulatory Advisor was invited to speak to large crowd of Med Spa owners following his recent visit to a Texas Med Spa. The fact that FDA has expedited enforcement of DSCSA regulations in the Med Spa industry comes out of necessity. There was evidence of a coordinated effort to use compounded products in place of their name-brand counterparts. A practice the FDA calls misbranding. It may increase margin in the short-term, but the increase comes at the expense of DSCSA violations and penalties in the long-run.
As one of the regulatory counsel involved in the Pure Indulgence Med Spa case, Mr. Weisbuch brought firsthand insight into what FDA inspectors look for during DSCSA compliance reviews. Having conducted inspections across three sites, he walked through the specific compliance expectations, documentation requirements, and operational gaps that can put businesses at risk. His session made one thing clear: DSCSA compliance is no longer a future concern for med spas. It is an active enforcement priority, and businesses that handle prescription drugs need to be prepared before an inspection occurs. It is always good to stay in touch with industry regulators and InfiniTrak truly appreciates all the time FDA Sr. Regulatory Advisor Aaron Weisbuch shared with our team of regulatory experts.
The conversations reinforced a consistent theme: while the med spa industry continues to grow rapidly, staying ahead of evolving regulations will be critical to protecting both patient safety and the long-term success of your business.
The FDA has initiated DSCSA enforcement out of necessity from bad actors in the wholesale and med spa community. It seems that a coordinated effort was made to acquire counterfeit products and avoid the DSCSA process. While the initial announcements involved med spas in Texas, the FDA is vigilant in acting on any manufacturer, wholesaler, and/or dispenser that does not put the necessary processes in place to assure drug safety throughout the U.S. drug supply chain.
Mr. Weisbuch also mentioned that the FDA is just one of the critical regulators that will be enforcing DSCSA, and that he expects the State Boards of Pharmacy to be very involved with dispensers in their states. Many states have already incorporated DSCSA into their audits, with more to follow. While the FDA cannot endorse one sole company for obvious reasons, it has been our custom to share time with regulators to stay ahead of the curve on what they expect and make sure that all compliance elements are fully covered.
Read the full FDA Inspection Letter for Texas Based Medical Spa Below: